Bayer HealthCare Plans $100 Million Product Testing Facility In Berkeley, California
04/15/2015
According to the firm, its investment represents the company's dedication to science and innovation in the life sciences. The Bay Area is the U.S. headquarters for research, development and biotech manufacturing for Bayer HealthCare.
"The new product testing facility will test Bayer's investigational products in accordance with rigorous global regulatory requirements," said David Weinreich, MD, Head, Global Development, Specialty Medicine at Bayer. "With today's announcement, we are thrilled to further strengthen our commitment to the hemophilia A patient community that Bayer has served for more than a quarter century."
"Building upon our legacy in hemophilia A, we are delighted to continue Bayer's leadership in working to bring treatment options to patients around the world," said Joerg Heidrich, Senior Vice President for Product Supply Biotech and Site Head at Bayer Berkeley. "As the Bay Area's third largest biotech employer, we are also proud to be making this contribution to the world's richest center of biotech R&D, investment, and production."
Project Announcements
Archer Plans Vernon, California, Production Operations
05/12/2025
Conagra Brands Expands Macon, Missouri, Operations
05/12/2025
LEGO Group Plans Prince George County, Virginia, Warehousing Operations
05/12/2025
AIRSYS Cooling Technologies Expands Spartanburg County, South Carolina, Operations
05/12/2025
Rivian Expands Normal, Illinois, Operations
05/10/2025
Oldcastle APG Plans Lancaster, South Carolina, Operations
05/10/2025
Most Read
-
Run a Job Task Analysis
Q4 2024
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
The Location Economics of Advanced Nuclear
Q1 2025
-
Why Workforce Readiness Can’t Wait
Q1 2025
-
Power, Policy, and Site Selection in 2025
Q1 2025
-
Is It Time to Start Planning for Quantum Data Centers?
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024